ClinicalTrials.Veeva

Menu

Cytomegalovirus Infection in Patients With HIV-1 Infection (ACTHIV)

U

University Hospital of Bordeaux

Status and phase

Completed
Phase 3

Conditions

HIV-1-infection
Cytomegalovirus Infections

Treatments

Procedure: Blood samples

Study type

Interventional

Funder types

Other

Identifiers

NCT04067869
CHUBX 2009/22

Details and patient eligibility

About

The purpose of this study is to assess the level of CD4 and CD8 T cell activation in an observational cohort study of HIV-1 patients, virosuppressed on combined antiretroviral therapy (< 50 copies/ml) for at least 2 years and to focus on two factors that could participate in this activation: cytomegalovirus infection and auto-immune disorders.

Full description

T cell activation plays a central role in HIV pathogenesis and is highly correlated to disease progression even in HIV patients virosuppressed on combined antiretroviral therapy since years. The mechanisms underlying this activation in virosuppressed patients are poorly understood. Identifying some factors involved in immune activation that can be targeted by therapies could optimize the treatment of HIV patients. The purpose of this study is to assess the level of CD4 and CD8 T cell activation in an observational cohort study of HIV-1 patients, virosuppressed on combined antiretroviral therapy (< 50 copies/ml) for at least 2 years and to focus on two factors that could participate in this activation: cytomégalovirus infection and auto-immune disorders.

Enrollment

392 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients included in the Aquitaine ANRS CO3 cohort aged 18 years or older (confirmed HIV-1 infection and at least one follow-up in the cohort),
  • plasma HIV-1 RNA <50 copies / ml for at least 24 months under a highly active antiretroviral combination (treatment comprising at least 3 antiretroviral drugs) modified or initiated between 2005 and 2008,
  • Follow-up in one of the departments of Bordeaux University Hospital or Libourne Hospital,
  • Free, informed and written consent, signed by the patient and the investigator (Consent of the Aquitaine CO3 Cohort and linked to this specific study).

Exclusion criteria

  • Presence of 2 consecutive measurements of HIV RNA> 50 copies / ml,
  • History of immunotherapy treatments (interleukin-2),
  • Hepatitis B or C co-infections,
  • Pregnancy
  • Breastfeeding
  • Symptomatic infectious episode in progress.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

392 participants in 1 patient group

Single arm
Experimental group
Description:
Patient with confirmed HIV-1 infection
Treatment:
Procedure: Blood samples

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems